Antiretroviral therapy improves renal function among HIV-infected Ugandans

Kidney International

Volumn 74, Issue 7, 2008, Pages 925-929

  Peters, Philip J ^a,b   Moore, David M ^c,d,e   Mermin, Jonathan ^c   Brooks, John T ^a   Downing, Robert ^c   Were, Willy ^c   Kigozi, Aminah ^c   Buchacz, Kate ^a   Weidle, Paul J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Africa; AIDS associated nephropathy; Highly active antiretroviral therapy; HIV; Renal insufficiency

Indexed keywords

CREATININE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE CLASSIFICATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME; UGANDA; WEIGHT GAIN; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CREATINE; FEMALE; HUMANS; MALE; RENAL INSUFFICIENCY; SEX FACTORS; TREATMENT OUTCOME; UGANDA; WEIGHT GAIN;

EID: 51849106368     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.305     Document Type: Article

References (31)

1. Gupta SK, Eustace JA, Winston JA et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of The Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585.
2. Winston JA, Burns GC, Klotman PE. The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy. Semin Nephrol 1998; 18: 373-377.
3. Choi AI, Rodriguez RA, Bacchetti P et al. The impact of HIV on chronic kidney disease outcomes. Kidney Int 2007; 72: 1380-1387.
4. Wyatt CM, Klotman PE. HIV-1 and HIV-associated nephropathy 25 years later. Clin J Am Soc Nephrol 2007; 2(Suppl 1): S20-S24.
5. Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. Kidney Int 2006; 69: 1885-1891.
6. Han TM, Naicker S, Ramdial PK et al. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006; 69: 2243-2250.
7. Wools-Kaloustian K, Gupta SK, Muloma E et al. Renal disease in an antiretroviral-naive HIV-infected outpatient population in Western Kenya. Nephrol Dial Transplant 2007; 22: 2208-2212.
8. Emem CP, Arogundade F, Sanusi A et al. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant 2008; 23: 741-746.
9. Kalayjian RC, Franceschini N, Gupta SK et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22: 481-487.
10. Lucas GM, Eustace JA, Sozio S et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18: 541-546.
11. Cosgrove CJ, bu-Alfa AK, Perazella MA. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci 2002; 323: 102-106.
12. Gallant JE, Parish MA, Keruly JC et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 1194-1198.
13. Zimmermann AE, Pizzoferrato T, Bedford J et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283-290.
14. Brodie SB, Keller MJ, Ewenstein BM et al. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS 1998; 12: 2433-2437.
15. Gardner LI, Holmberg SD, Williamson JM et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 203-209.
16. Szczech LA, Gange SJ, van der HC et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61: 195-202.
17. Winston JA, Klotman ME, Klotman PE. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 1999; 55: 1036-1040.
18. Shahinian V, Rajaraman S, Borucki M et al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000; 35: 884-888.
19. Szczech LA, Gupta SK, Habash R et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66: 1145-1152.
20. Atta MG, Gallant JE, Rahman MH et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21: 2809-2813.
21. Kirchner JT. Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature. AIDS Read 2002; 12: 103-1012.
22. Wali RK, Drachenberg CI, Papadimitriou JC et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998; 352: 783-784.
23. Reid A, Stohr W, Walker S et al. Glomerular dysfunction and associated risk factors following initiation of ART in adults with HIV infection in Africa (abstract THAB0105). In: Program and Abstracts of the 16th International AIDS Conference (Toronto, Canada) Toronto, Canada: International AIDS Society, 2006.
24. Heald A, Yuen G, Mydlow P et al. Optimal estimation of glomerular filtration rate in patients infected with human immunodeficiency virus (abstract no. 114). In: the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Orlando: Florida, 1994.
25. Kotler DP, Glyptis A, Grunfeld C et al. Systematic errors in estimating renal function by Cockcroft-Gault (CG) or modification of diet in renal disease (MDRD) equations (abstract 18). In: the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV San Francisco, California, 2006.
26. Weidle PJ, Wamai N, Solberg P et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006; 368: 1587-1594.
27. Buchacz K, Weidle PJ, Moore D et al. Changes in Lipid Profile over 24 Months among Adults on First-Line HAART in the Home-Based AIDS Care (HBAC) Program in Rural Uganda. J Acquir Immune Defic Syndr 2008; 47: 304-311.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
29. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
30. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 29 January 2008; pp 1-128. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.Accessed on 7 March 2008, Table 16: pp 75-76.
31. NIH Division of AIDS NIH Division of AIDS 2004. Available at http://rcc.tech-res.com/tox_tables.htm.Accessed 20 September 2007.